<DOC>
	<DOC>NCT02348879</DOC>
	<brief_summary>This study is to evaluate the safety of AMG 403 in healthy adult subjects. The study consists of a 21 day screening period followed by administration of the investigational product and up to 154 day evaluation period.</brief_summary>
	<brief_title>A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Healthy men and women of nonchild bearing potential, Between the ages of 18 and 55 inclusive, Body mass index from 18 to 33 kg/m2, Skin type compatible with the study assessments, and without significant skin allergies, pigmentary disorders, tattoos, or any active dermatologic conditions that might interfere with the study conduct. Prior or current history of peripheral neuropathy, paraesthesias, dysesthesias, herpes zoster, postherpetic neuralgia, Evidence of any current illness such as a common cold, viral syndrome, or flulike symptoms, any disturbance of the autonomic nervous system, History of Raynaud's phenomenon; Know allergy or intolerance to capsaicin or hot peppers.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>